Hmm… Me pregunto si tendria que empezar a mirar Eurofins?
Rival contract manufacturers stand to benefit from the bill. “We are seeing an increase in engagement,” said Mario Polywka, interim chief executive of Evotec, a German drug outsourcer that focuses on early drug development.
Fujifilm Diosynth, another contract manufacturer, said it had received “exploratory inquiries” about “potential supply chain resiliency challenges”, following talks over the Biosecure Act and the acquisition in February of major contract manufacturer Catalent by Novo Holdings, the parent company of Novo Nordisk.
WuXi has been coming under increasing pressure in the US. In March, the Biotechnology Innovation Organization (Bio), a US-based trade body that represents more than 1,200 biotechs worldwide, came out in support of the bill and cut ties with WuXi companies, after US lawmakers asked the US justice department to investigate Bio’s advocacy for WuXi.
John Crowley, Bio’s newly appointed chief executive who used WuXi’s services when he ran Amicus Therapeutics, said the US pharmaceutical sector would “take years to extract ourselves from China, as it is going to with the semiconductor industry”.
Pharma groups and biotechs can be locked into contracts with WuXi for up to five years into the future, said Crowley